Fundraising FoxKdT Ventures — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.
BiotechDeep TechSan Carlos, US
Matthew Hill(Executive Officer, Director)in
BoardPeter Zhou(Director)inJonathan Sheena(Director)in
Board seatCain McClary· per SEC Form D
Co-investorsACVC PartnersAndreessen HorowitzIn-Q-TelRaptor GroupTriatomic CapitalAME Cloud Ventures+1 more
ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.
BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US
Harshal Chokhawala(Chief Executive Officer & Co-Founder)inLindy Fishburne(Director)Phil Grayeski(Director)Taehong Huh(Director)Timothy Dummer(Executive Officer, Director)Jon Kuchenreuther(Co-Founder)
Board seatPhil Grayeski· per SEC Form D
Co-investorsAccelr8Breakout LabsBreakout VenturesCavallo VenturesDudley FundFreshTracks Capital+8 more
Exthymic is a company working on cell therapy manufacturing, aiming to make cancer cell therapies more accessible to patients who currently cannot obtain them.
BiotechHealthtechSan Diego, US
Rich Stoner(Founder)inDan Knudsen(Founder)Kevin Cooksy(Founder)in
Co-investorsHAWKTAILPhase Two Ventures
Motif Neurotech develops a therapeutic brain-computer interface using minimally invasive neuromodulation to treat difficult-to-treat mental health conditions such as depression.
BiotechDeep TechDigital HealthHealthtechMedical DevicesHouston, US
Sameer Sheth(Founder)inSunil Sheth(Founder)Nick Halper(Chief Operating Officer)inSteve Goetz(Chief Technology Officer)inAnthony Arnold(Director)inKaiyuan Yang(Founder)
Co-investorsArboretum VenturesDivergent CapitalDolby Family VenturesFeatures Capital HoldingsPsyMed VenturesTMC Venture Fund+6 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.